Glaukos Reports Positive Epioxa Trial Results and Signs New Licensing Deal

Key Facts

1Glaukos Corporation reported positive three-year trial results for its Epioxa treatment for keratoconus.

2The company secured an exclusive licensing deal to expand its pipeline of retinal disease therapies.

Glaukos Corporation reported positive three-year trial results for its Epioxa treatment for keratoconus. Reuters reported that the company also secured an exclusive licensing deal to expand its pipeline of retinal disease therapies.

GKOS closed at $172.18 on October 7, 2026, after trading between a low of $159.59 and a high of $174.48 during the session. These clinical and strategic developments come as the company seeks to strengthen its position in the ophthalmic therapy market by validating existing treatments and acquiring new pipeline assets.